Skip to main content

Macrogen establishes foothold in Basel

| News

Macrogen establishes foothold in Basel


Macrogen Europe is set to move into the Switzerland Innovation Park Basel Area at Novartis Campus. As with its parent company, the South Korean biotechnology firm Macrogen Inc., the European subsidiary specializes as a service provider in the area of Sanger sequencing for genome research activities.

Bongcho Kim, CEO Macrogen Europe (image: Macrogen)

Macrogen Europe is seeking to expand within Switzerland from its foothold in Basel with its Sanger sequencing laboratory. To this end, the company, whose European headquarters are located in Amsterdam, with primary headquarters in the South Korean capital Seoul, has chosen the Novartis Campus site of the Switzerland Innovation Park Basel Area. The Swiss Business Hub Korea, which represents the official Swiss consultancy, promotion and platform organization for export and investment promotion, Switzerland Global Enterprise, in Seoul, initiated the first contact with the investment and innovation promotion agency Basel Area Business & Innovation.

This year, Macrogen Europe was named Top Sanger Sequencing Services Company 2023 by the North American biotech magazine “Life Sciences Review”. Since 2008, Macrogen Europe has been focused on supporting genomics researchers in Europe and Africa. With its Sanger and Next Generation sequencing laboratories, the company claims to be able to ensure fast turnaround times.

Existing life sciences cluster as reason for settlement

“Our powerful sequencing services are designed to take up as little research time as possible, because project delays are simply not an option for us”, comments Bongcho Kim, CEO of Macrogen Europe, before adding: “Our plan for Basel is to expand within Switzerland with our in-house laboratory sequencing”.

Initially, the company intends to move closer to its customers with two employees in Basel. Thereafter, the plan is to gradually increase the local workforce to between five and ten staff members at a physical lab in Switzerland. In terms of the reasoning behind choosing Basel, Macrogen cites the appeal of the existing life sciences cluster and central location on the border with Germany and France.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.